BioGaia AB (publ) (LON:0GTN)

Market Cap	876.87M +1.4%
Revenue (ttm)	115.46M +7.9%
Net Income	24.94M -6.2%
EPS	0.25 -6.4%
Shares Out	n/a
PE Ratio	35.16
Forward PE	27.57
Dividend	0.54 (0.49%)
Ex-Dividend Date	May 8, 2025

Volume	7,584
Average Volume	24,083
Open	108.20
Previous Close	108.85
Day's Range	106.00 - 108.20
52-Week Range	93.60 - 134.60
Beta	0.42
RSI	43.11
Earnings Date	Feb 12, 2026

About BioGaia AB

BioGaia AB (publ), a healthcare company, develops, manufactures, markets and sells probiotic products for gut, oral, and immune health in Europe, the Middle East, Africa, the United States, the Asia-Pacific, Australia, and New Zealand. It operates through Pediatrics, Adult Health, and Other segments. The Pediatrics segment offers drops, oral rehydration solutions, and gut health tablets, as well as cultures that are used as an ingredient in infant formula and milk formula. The Adult Health segment provides gut health tablets, bone health tablet...

• Industry: Pharmaceutical Preparations
• Founded: 1990
• Employees: 238
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0GTN

Financial Performance

In 2025, BioGaia AB's revenue was 1.54 billion, an increase of 8.11% compared to the previous year's 1.42 billion. Earnings were 332.76 million, a decrease of -5.30%.

Financial numbers in SEK